Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft model

Luo,Xuwen; Liu,Xuqiang; Tao,Qianyuan; Yao,Cong; Wang,Fuqiang; Gu,Zhiping; Li,Feilong; Yu,Xiaolong; Zhang,Bin; Fan,Hongxian; Dai,Min; Nie,Tao

doi:10.3892/ol.2020.11656

Enoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft model

Authors:
- Xuwen Luo
- Xuqiang Liu
- Qianyuan Tao
- Cong Yao
- Fuqiang Wang
- Zhiping Gu
- Feilong Li
- Xiaolong Yu
- Bin Zhang
- Hongxian Fan
- Min Dai
- Tao Nie
View Affiliations

Affiliations: Department of Orthopaedics, The First Affiliated Hospital of Nanchang University, Artificial Joints Engineering and Technology Research Centre of Jiangxi Province, Nanchang, Jiangxi 330006, P.R. China
Published online on: May 21, 2020 https://doi.org/10.3892/ol.2020.11656
Pages: 1400-1408
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most prevalent primary bone malignancy in children and adolescents. Neoadjuvant chemotherapy combined with surgical resection, the current standard treatment of osteosarcoma, is associated with a 5‑year survival rate of only ~70%. Therefore, it is necessary to identify new, more effective treatment strategies for patients with this lethal disease. Enoxacin is a highly effective broad‑spectrum fluoroquinolone antibiotic with low toxicity. The drug inhibits the growth and metastasis of numerous tumour types, but its efficacy has not been studied in osteosarcoma. This study assessed the antitumour effects of enoxacin in osteosarcoma 143B cells and in a murine tumour xenograft model. Enoxacin inhibited the proliferation, invasion and migration of 143B cells, as well as inducing their apoptosis. These effects were thought to be mediated by downregulation of Bcl‑xL, Bxl‑2, matrix metalloproteinase (MMP)2 and MMP9 expression. Enoxacin also significantly impaired the growth of bone tumours in nude mice without affecting their liver or kidney function, or blood cell count. Collectively, these results indicate that enoxacin is a promising new drug for osteosarcoma that warrants further evaluation in clinical studies.

View Figures

View References

1	Delebinski CI, Georgi S, Kleinsimon S, Twardziok M, Kopp B, Melzig MF and Seifert G: Analysis of proliferation and apoptotic induction by 20 steroid glycosides in 143B osteosarcoma cells in vitro. Cell Prolif. 48:600–610. 2015. View Article : Google Scholar : PubMed/NCBI
2	Liu SY, Deng SY, He YB and Ni GX: miR-451 inhibits cell growth, migration and angiogenesis in human osteosarcoma via down-regulating IL 6R. Biochem Biophys Res Commun. 482:987–993. 2017. View Article : Google Scholar : PubMed/NCBI
3	Zhang J, Hou W, Chai M, Zhao H, Jia J, Sun X, Zhao B and Wang R: MicroRNA-127-3p inhibits proliferation and invasion by targeting SETD8 in human osteosarcoma cells. Biochem Biophys Res Commun. 469:1006–1011. 2016. View Article : Google Scholar : PubMed/NCBI
4	Isakoff MS, Bielack SS, Meltzer P and Gorlick R: Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
5	Gao JZ, Chen FH, Wang L, Wei H and Meng SL: YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma. Eur Rev Med Pharmacol Sci. 19:2062–2069. 2015.PubMed/NCBI
6	Brown HK, Tellez-Gabriel M and Heymann D: Cancer stem cells in osteosarcoma. Cancer Lett. 386:189–195. 2017. View Article : Google Scholar : PubMed/NCBI
7	Wise R, Andrews JM and Danks G: In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents. J Antimicrob Chemother. 13:237–244. 1984. View Article : Google Scholar : PubMed/NCBI
8	Cao S, Sun R, Wang W, Meng X, Zhang Y, Zhang N and Yang S: RNA helicase DHX9 may be a therapeutic target in lung cancer and inhibited by enoxacin. Am J Transl Res. 9:674–682. 2017.PubMed/NCBI
9	Mondal ER, Das SK and Mukherjee P: Comparative evaluation of antiproliferative activity and induction of apoptosis by some fluoroquinolones with a human non-small cell lung cancer cell line in culture. Asian Pac J Cancer Prev. 5:196–204. 2004.PubMed/NCBI
10	Sousa E, Graça I, Baptista T, Vieira FQ, Palmeira C, Henrique R and Jerónimo C: Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. Epigenetics. 8:548–558. 2013. View Article : Google Scholar : PubMed/NCBI
11	Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas L, et al: Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA. 108:4394–4399. 2011. View Article : Google Scholar : PubMed/NCBI
12	Bhanot SK, Singh M and Chatterjee NR: The chemical and biological aspects of fluoroquinolones: Reality and dreams. Curr Pharm Des. 7:311–335. 2001. View Article : Google Scholar : PubMed/NCBI
13	Sampo M, Koivikko M, Taskinen M, Kallio P, Kivioja A, Tarkkanen M and Böhling T: Incidence, epidemiology and treatment results of osteosarcoma in Finland-a nationwide population-based study. Acta Oncol. 50:1206–1214. 2011. View Article : Google Scholar : PubMed/NCBI
14	Mirabello L, Troisi RJ and Savage SA: International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
15	Dai X, Ma W, He X and Jha RK: Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma. Med Sci Monit. 17:RA177–RA190. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ando K, Heymann MF, Stresing V, Mori K, Rèdini F and Heymann D: Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013. View Article : Google Scholar : PubMed/NCBI
17	Lamoureux F, Trichet V, Chipoy C, Blanchard F, Gouin F and Redini F: Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
18	Picci P: Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
19	Li Y, Liao Q, Li K, Zhong D, Weng X and Mi M: Knockdown of endothelin A receptor expression inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model. Mol Med Rep. 5:1391–1395. 2012.PubMed/NCBI
20	Kato H, Wakabayashi H, Naito Y, Kato S, Nakagawa T, Matsumine A and Sudo A: Anti-tumor necrosis factor therapy inhibits lung metastasis in an osteosarcoma cell line. Oncology. 88:139–146. 2015. View Article : Google Scholar : PubMed/NCBI
21	Meazza C and Scanagatta P: Metastatic osteosarcoma: A challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
22	Shay G, Lynch CC and Fingleton B: Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 44-46:200–206. 2015. View Article : Google Scholar : PubMed/NCBI
23	Jabłońska-Trypuć A, Matejczyk M and Rosochacki S: Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Suppl 1):S177–S183. 2016. View Article : Google Scholar
24	Zhu KP, Ma XL and Zhang CL: LncRNA ODRUL contributes to osteosarcoma progression through the miR-3182/MMP2 Axis. Mol Ther. 25:2383–2393. 2017. View Article : Google Scholar : PubMed/NCBI
25	Qiu R, Li X, Qin K, Chen X, Wang R, Dai Y, Deng L and Ye Y: Antimetastatic effects of calycosin on osteosarcoma and the underlying mechanism. Biofactors. 45:975–982. 2019. View Article : Google Scholar : PubMed/NCBI
26	Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778. 2016. View Article : Google Scholar : PubMed/NCBI
27	Silvestris F, Ribatti D, Nico B, Silvestris N, Romito A and Dammacco F: Apoptosis or programmed cell death: Regulatory and pathophysiological mechanisms. Ann Ital Med Int. 10:7–13. 1995.(In Italian). PubMed/NCBI
28	Cardenas C, Montagna MK, Pitruzzello M, Lima E, Mor G and Alvero AB: Adipocyte microenvironment promotes Bcl_xl expression and confers chemoresistance in ovarian cancer cells. Apoptosis. 22:558–569. 2017. View Article : Google Scholar : PubMed/NCBI
29	Park SS, Lee DM, Lim JH, Lee D, Park SJ, Kim HM, Sohn S, Yoon G, Eom YW, Jeong SY, et al: Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis. Carcinogenesis. 39:458–470. 2018. View Article : Google Scholar : PubMed/NCBI
30	Committee on Infectious Diseases: The use of systemic fluoroquinolones. Pediatrics. 118:1287–1292. 2006. View Article : Google Scholar : PubMed/NCBI
31	Hampel B, Hullmann R and Schmidt H: Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use-safety report. Pediatr Infect Dis J. 16:127–129, 160-162. 1997. View Article : Google Scholar : PubMed/NCBI
32	Bacci C, Galli L, de Martino M and Chiappini E: Fluoroquinolones in children: Update of the literature. J Chemother. 27:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
33	Huvos AG: Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer. 57:1442–1449. 1986. View Article : Google Scholar : PubMed/NCBI